X

Trial Profile

A Multicenter Expanded Access Treatment Protocol of Lurbinectedin (PM01183) in Previously Treated Small Cell Lung Cancer in the USA

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 25 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lurbinectedin (Primary)
Indications Small cell lung cancer
Focus Expanded access; Therapeutic Use
Sponsors Jazz Pharmaceuticals Inc; PharmaMar

Most Recent Events

17 Jun 2020 Status changed from recruiting to completed.
11 May 2020 According to a Jazz Pharmaceuticals Inc media release, this expanded access program (EAP) has been transitioned from Pharmamar to Jazz Pharmaceuticals. Now Bionical Emas and Jazz Pharmaceuticals will be working on this EAP.
29 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com